CD200R1 and neoplasm: More specifically, upon binding to CD200R on NK cells, sCD200 inhibits the MAPK/ERK pathway, suppressing tumor cell killing via the inhibition of IFN-γ release and promoting NK cell apoptosis via upregulated production of pro-apoptotic genes, including Fas, Fas ligand, and FADD (17).